Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054]
1 Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
2 Department of Public Health, University of Naples "Federico II", Naples, Italy.
3 Oncologia Medica, Fondazione S. Maugeri IRCCS, Pavia, Italy.
4 Department of Oncology, S. Luca Hospital, Lucca, Italy.
5 Unit of Oncology, A.O.R.N. dei Colli, Napoli, Naples, Italy.
6 Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
7 Medical Oncology Unit, ASL Frosinone, Frosinone, Italy.
8 UO Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
9 Department of Oncology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.
10 Breast Oncology Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy.
11 Azienda Ospedaliera Universitaria Pisana, Ospedale Santa Chiara, Pisa, Italy.
12 UO Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; University of Genova, Dipartimento di Medicina Interna e Specialità Mediche (DIMI), Genova, Italy.
13 Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy. Electronic address: [email protected].